<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45455">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514525</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0011</org_study_id>
    <nct_id>NCT02514525</nct_id>
  </id_info>
  <brief_title>Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System</brief_title>
  <acronym>ColdPlay3</acronym>
  <official_title>Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients With Previously Untreated Dysplastic Barrett's Epithelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C2 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C2 Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of the CryoBalloon Focal Ablation System for the
      treatment of previously-untreated (&quot;treatment naïve&quot;) Barrett's Esophagus (BE)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coldplay 3 is a multi-center, prospective study that will provide evidence of the efficacy
      and safety of the System in treatment of patients with previously untreated (treatment
      naïve) low grade dysplasia (LGD) or high grade dysplasia (HGD) BE. Subjects may have a
      maximum of five (5) ablation treatment sessions during their 12 months of study
      participation to achieve complete eradication of their dysplastic BE and intestinal
      metaplasia. As many ablations as needed to treat the dysplastic areas are allowed in each
      treatment session at the discretion of the investigator.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of serious, CryoBalloon Ablation System-related adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients with baseline LGD who have complete eradication of all dysplasia</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of patients with baseline HGD who have complete eradication of all dysplasia</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of all treated patients who have complete eradication of all dysplasia (CE-D)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with complete eradication of all esophageal intestinal metaplasia (CE-IM)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with progression of dysplasia from LGD to HGD or esophageal cancer, or progression of HGD to cancer</measure>
    <time_frame>12 months</time_frame>
    <description>For Baseline LGD and HGD subjects: progression of dysplasia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all treatment-related and all serious, non-treatment-related adverse events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post procedure chest discomfort events / Pain score &gt;0 and &lt;5</measure>
    <time_frame>Day 1</time_frame>
    <description>(scored on a 0-10 visual analog pain scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post procedure chest discomfort events / Pain score ≥5 and requiring narcotic analgesic</measure>
    <time_frame>Day 1</time_frame>
    <description>(scored on a 0-10 visual analog pain scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Median Pain score on Day 1 post procedure</measure>
    <time_frame>Day 1</time_frame>
    <description>(scored on a 0-10 visual analog pain scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Median Pain score on Day 7 post procedure</measure>
    <time_frame>Day 7</time_frame>
    <description>(scored on a 0-10 visual analog pain scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of (CE-D) and all esophageal (CE-IM) will be reported as a percentage of all subjects enrolled, and stratified by baseline dysplasia grade</measure>
    <time_frame>24 and 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CryoBalloon ablation treatments required to achieve CE-D or CE-IM</measure>
    <time_frame>12 months</time_frame>
    <description>(mean and median)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Barrett Esophagus</condition>
  <arm_group>
    <arm_group_label>CryoBalloon Ablation System</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cryoablation treatment of patients with previously untreated (treatment naïve) Barrett's epithelium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CryoBalloon Ablation System</intervention_name>
    <description>CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.</description>
    <arm_group_label>CryoBalloon Ablation System</arm_group_label>
    <other_name>CryoBalloon Focal Ablation System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low- or high-grade non-nodular, previously untreated (&quot;treatment naïve&quot;) dysplastic
             BE, confirmed by histopathological analysis. If nodular BE or Intramuscosal Cancer
             (ImCA) is identified during patient screening, this may be treated with Endoscopic
             Mucosal Resection (EMR) ≥6 weeks prior to treatment under this protocol. If previous
             EMR was performed, follow-up endoscopy must be negative for nodular BE. Patients with
             ImCA must be at low risk for recurrence, confirmed by EMR pathology results negative
             for positive margin, poorly differentiated carcinoma, and lymphovascular invasion.

          -  BE length ≤6cm excluding visible BE islands, and Prague Classification C ≥0 / M ≥1

          -  Older than 18 years of age at time of consent

          -  Operable per institution's standards

          -  Provides written informed consent on the approved informed consent form

          -  Willing and able to comply with study requirements for follow-up

        Exclusion Criteria:

          -  Non-dysplastic or indefinite for dysplasia BE, confirmed by histopathological
             analysis

          -  Esophageal stenosis/stricture preventing advancement of a therapeutic endoscope
             (patients may have the stenosis/stricture dilated and then be treated with
             CryoBalloon ablation under this protocol at a subsequent procedure ≥2 weeks later)

          -  Symptomatic untreated strictures

          -  Endoscopically-visualized abnormalities such as masses or nodules within 4cm of the
             treatment zone. Neoplastic nodules must first be treated with EMR ≥6 weeks prior to
             planned treatment under this protocol.

          -  History of esophageal cancer more extensive than T1a or not meeting criteria for low
             risk of recurrence (confirmed by EMR pathology results negative for positive margin,
             poorly differentiated carcinoma, and lymphovascular invasion)

          -  History of esophageal varices

          -  Large (&gt;4cm) hiatal hernia

          -  Prior distal esophagectomy

          -  Any clinical or histological suspicion of esophageal adenocarcinoma invading into the
             submucosa by endoscopic mucosal resection (EMR), or confirmed T1a cancer with
             positive deep margin by EMR

          -  Active esophagitis grade B or higher

          -  Severe medical comorbidities precluding endoscopy

          -  Uncontrolled coagulopathy

          -  Pregnant or planning to become pregnant during period of study participation

          -  Patient refuses or is unable to provide written informed consent

          -  Life expectancy ≤3 years, as judged by the site investigator

          -  General poor health, multiple co-morbidities placing the patient at risk or otherwise
             unsuitable for trial participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcia Canto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcia Wachna, RN</last_name>
    <phone>650-996-2183</phone>
    <email>marcia@c2therapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcia Canto, MD</last_name>
    <phone>410-964-5199</phone>
    <email>mcanto@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kianoush Donboli</last_name>
      <phone>773-926-8490</phone>
      <email>kdonboli@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Irving Waxman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Cosby, RN</last_name>
      <phone>410-502-2893</phone>
      <email>hcosby1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Mimi Canto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Johnson</last_name>
      <phone>507-293-5307</phone>
      <phone_ext>3-5307</phone_ext>
      <email>johnson.michele@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Prasad G. Iyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital-Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Kim</last_name>
      <phone>212-305-1820</phone>
      <email>hk2933@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Julian Abrams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Onyenwoke, MS, RD, LDN</last_name>
      <phone>919-943-0821</phone>
      <email>aco16@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Nicholas J. Shaheen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Ahuja Medical Center</name>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Brock, RN</last_name>
      <phone>216-844-3853</phone>
      <email>wendy.brock@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Amitabh Chak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Brock, RN</last_name>
      <phone>216-844-3853</phone>
      <email>wendy.brock@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Amitabh Chak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Kopfinger, RN</last_name>
      <phone>570-214-5420</phone>
      <email>mckopfinger@geisinger.edu</email>
    </contact>
    <investigator>
      <last_name>David Diehl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Matthews</last_name>
      <phone>215-503-2545</phone>
      <email>Michael.Matthews@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Anthony Infantolino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>July 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
